Overview
This recorded webinar highlights how AstraZeneca leveraged the unique capabilities of the Intellicyt iQue® Screener platform to run a 500 thousand compound cell viability screen and a target specific bead-based assay involving three of the major risk genes/factors associated with Amyotrophic Lateral Sclerosis (ALS) to identify novel inhibitors of target-induced toxicity.
